# Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)

> **NCT05402332** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Eva Morava-Kozicz** · enrollment: 8 (estimated)

## Conditions studied

- PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation

## Interventions

- **DRUG:** AVTX-801
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05402332
- **Lead sponsor:** Eva Morava-Kozicz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-03-02
- **Final completion:** 2028-03-02
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05402332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05402332, "Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05402332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*